GO
Loading...

Enter multiple symbols separated by commas

Stocks Sanofi SA

More

  • Plant 'milkers' seek molecules for medicines and make-up Wednesday, 22 Jul 2015 | 8:43 AM ET

    *Companies including BASF and Chanel have teamed up with PAT. LARONXE, France, July 22- A quiet village in eastern France is home to an unusual greenhouse. Several major companies, including German chemicals group BASF and French cosmetics maker Chanel, have teamed up with Plant Advanced Technologies in the hope of securing privileged access to the so-called...

  • July 21- Amgen Inc's cholesterol fighting drug was approved by the European Commission, giving the keenly anticipated treatment a head start over a rival drug being developed by Regeneron Pharmaceuticals Inc and Sanofi SA. Amgen did not immediately reveal when the drug would be available or its pricing strategy. Amgen's drug is designed for biweekly doses of...

  • PARIS, July 15- Sanofi will adopt a simplified structure centred around five global business units starting in January 2016 to promote growth, the French drugmaker said on Wednesday, as it prepares a new strategic plan to be unveiled in November. The composition of Sanofi's executive committee remains unchanged, the company said. The reorganisation is...

  • Europe stocks close higher after Greek deal reached Monday, 13 Jul 2015 | 11:30 AM ET

    European equities ended sharply higher on Monday after European negotiators reached a deal over a third bailout for Greece.

  • Seprafilm, developed by Genzyme, is used to reduce abnormal internal scarring following surgery, by separating tissues and organs while they heal. The FDA and Genzyme, which was bought by Sanofi in 2011, were not immediately available for comment. FDA database of Manufacturer and User Facility Device Experience cites at least nine reports that link Seprafilm...

  • July 7- Consumer watchdog Public Citizen said it petitioned the U.S. health regulators to withdraw approval of Sanofi SA's Seprafilm and order a recall, saying the surgical implant has been associated with side effects including death. Seprafilm, developed by Genzyme, is used to reduce abnormal internal scarring following surgery, by separating tissues and...

  • BASEL, Switzerland, June 29- Drugmakers said on Monday they would continue to ship medicines to Greece in coming weeks, despite mounting unpaid bills, but warned supplies could be in jeopardy if Europe did not take emergency action. A copy of the letter to EU Health Commissioner Vytenis Andriukaitis from Richard Bergstrom, director general of the European...

  • June 26- Drug developer Celladon Corp said on Friday it may liquidate itself if it were unable to find a buyer, and was suspending development of its gene therapy for heart failure. Celladon said if it were to liquidate during the third quarter ending September, the net cash available for distribution to shareholders would be about $25 million- $30 million.

  • New drug compound may beat malaria with single $1 dose Wednesday, 17 Jun 2015 | 1:00 PM ET

    LONDON, June 17- Scientists have discovered a new anti-malarial compound that could treat patients with a single $1 dose, including those with strains of the mosquito-borne disease that are resistant to current drugs. In a vote of confidence for the project, German drugmaker Merck KgAA has secured the right to develop and commercialize the compound, assuming...

  • Why a FDA nod isn't enough for Regeneron shares Wednesday, 10 Jun 2015 | 12:49 PM ET
    A technician at Regeneron Pharmaceuticals headquarters in Tarrytown, N.Y.

    Regeneron's shares sank 4 percent despite a positive Food and Drug Administration recommendation on a cholesterol drug. What gives?

  • FDA panel backs first-in-class cholesterol drug Wednesday, 10 Jun 2015 | 8:44 AM ET
    Leonard Schliefer, CEO of Regeneron.

    Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with a caveat.

  • Early movers: TGT, PRU, CL, NFLX, AAPL & more Wednesday, 10 Jun 2015 | 7:51 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • The Swiss drugmaker, which has licensed rights to dalcetrapib to Quebec- based DalCor Pharmaceuticals, said on Tuesday it would provide a companion diagnostic for use in the Phase III study. DalCor estimates about $250 million will be needed for the project, which will be run in collaboration with the Montreal Heart Institute and will screen more than 30,000...

  • June 7- Novo Nordisk's IDegLira combination drug for type 2 diabetes led to significant reductions in blood sugar, weight and rate of hypoglycemia compared with Sanofi's top-selling Lantus insulin product, according to data from a late-stage trial presented at a medical meeting on Sunday. In the 26- week, 557- patient phase III study presented at the ADA...

  • June 6- A long-acting insulin being developed by Eli Lilly and Co demonstrated greater blood sugar reduction than Sanofi SA's top-selling Lantus in patients with type 2 diabetes, according to data from three Phase III trials presented on Saturday. More patients in the studies who received Lilly's basal insulin peglispro also got their blood sugar down to the...

  • *Wall St banks say September rate hike more likely. Wall Street's top banks said they expect the Fed to begin raising interest rates in September, followed by another increase before the end of the year, according to a Reuters poll. "The market is excited about stronger jobs and higher wages, but before can pop the cork of the champagne bottle, they start thinking...

  • WASHINGTON, June 5- An experimental drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday before a meeting on Tuesday of a panel of outside advisers to the FDA who will discuss...

  • WASHINGTON, June 5- A drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday on the FDA's website before a meeting Tuesday of a panel of outside advisers who will discuss the drug...

  • The three best global stocks to buy now: Expert Thursday, 4 Jun 2015 | 6:00 AM ET
    A toy bull figurine sits on a trader's computer screen as the DAX Index curve sits on a board beyond at the Frankfurt Stock Exchange in Frankfurt, Germany.

    Three names present the world's best opportunities now, says Erin Gibbs of S&P Capital IQ.

  • Linking cancer drug prices to their performance Wednesday, 27 May 2015 | 1:54 PM ET

    Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.